BR112023004020A2 - Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r - Google Patents

Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r

Info

Publication number
BR112023004020A2
BR112023004020A2 BR112023004020A BR112023004020A BR112023004020A2 BR 112023004020 A2 BR112023004020 A2 BR 112023004020A2 BR 112023004020 A BR112023004020 A BR 112023004020A BR 112023004020 A BR112023004020 A BR 112023004020A BR 112023004020 A2 BR112023004020 A2 BR 112023004020A2
Authority
BR
Brazil
Prior art keywords
methods
antagonist
asthma
administration
treatment
Prior art date
Application number
BR112023004020A
Other languages
English (en)
Inventor
Xu Christine
AKINLADE Bolanle
Amin Nikhil
Ruddy Marcella
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of BR112023004020A2 publication Critical patent/BR112023004020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS PARA TRATAMENTO DE ASMA EM INDIVÍDUOS PEDIÁTRICOS ATRAVÉS DA ADMINISTRAÇÃO DE UM ANTAGONISTA DE IL-4R. Métodos para tratar ou prevenir asma em um indivíduo pediátrico. São fornecidos métodos que compreendem administrar a um indivíduo pediátrico que precisa uma composição terapêutica que compreende um antagonista do receptor de interleucina-4 (IL-4R), tal como um anticorpo anti-IL-4R ou fragmento de ligação a antígeno do mesmo.
BR112023004020A 2020-10-05 2021-10-04 Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r BR112023004020A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063087668P 2020-10-05 2020-10-05
US202063109719P 2020-11-04 2020-11-04
US202163144048P 2021-02-01 2021-02-01
US202163157922P 2021-03-08 2021-03-08
EP21315151 2021-08-31
PCT/US2021/053328 WO2022076289A1 (en) 2020-10-05 2021-10-04 Methods for treating asthma in pediatric subjects by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
BR112023004020A2 true BR112023004020A2 (pt) 2023-04-25

Family

ID=78414079

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004020A BR112023004020A2 (pt) 2020-10-05 2021-10-04 Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r

Country Status (9)

Country Link
US (1) US20220169739A1 (pt)
EP (1) EP4225436A1 (pt)
JP (1) JP2023544406A (pt)
KR (1) KR20230082650A (pt)
AU (1) AU2021357078A1 (pt)
BR (1) BR112023004020A2 (pt)
CA (1) CA3194111A1 (pt)
MX (1) MX2023003942A (pt)
WO (1) WO2022076289A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
WO2024011251A1 (en) * 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
PT2769992T (pt) 2006-10-02 2021-03-11 Regeneron Pharma Anticorpos humanos com elevada afinidade para o receptor de il-4 humana
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US8945559B2 (en) 2010-10-06 2015-02-03 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
PT3973987T (pt) * 2014-09-15 2024-04-01 Regeneron Pharma Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CA3079946A1 (en) * 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도

Also Published As

Publication number Publication date
WO2022076289A1 (en) 2022-04-14
KR20230082650A (ko) 2023-06-08
US20220169739A1 (en) 2022-06-02
JP2023544406A (ja) 2023-10-23
AU2021357078A1 (en) 2023-06-15
MX2023003942A (es) 2023-06-02
EP4225436A1 (en) 2023-08-16
CA3194111A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
PH12017501934A1 (en) Methods for treating or preventing migraine headache
BR112021021195A2 (pt) Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
BR112015013095A8 (pt) Cânula nasal para distribuição de gás terapêutico a um paciente
BR112022000377A2 (pt) Métodos para o tratamento de dermatite atópica por administração de antagonista de il-4r
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
BR112023004020A2 (pt) Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
EA201491358A1 (ru) Вводимые перорально кортикостероидные композиции
BR112022015363A2 (pt) Uso de um antagonista do receptor de interleucina-4 (il-4r), composição farmacêutica e recipiente para tratar dermatite atópica (da) ou melhorar um parâmetro associado à da em um indivíduo
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112018008893A8 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
BR112022000740A2 (pt) Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
BR112022011388A2 (pt) Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
BR112021023372A2 (pt) Método para o tratamento do câncer com uma forma de dosagem oral de um receptor de inibidor-alfa de estrogênio
BR112022010934A2 (pt) Métodos para tratar copd administrando um antagonista de il-33